Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update Life Science Investing
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update Life Science Investing
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ Biotech Investing
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026 Life Science Investing
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results Life Science Investing
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes Life Science Investing
